Dova Pharmaceuticals Stock Price, News & Analysis (NASDAQ:DOVA)

$34.68 +0.78 (+2.30 %)
(As of 02/20/2018 06:30 AM ET)
Previous Close$33.90
Today's Range$31.09 - $35.00
52-Week Range$16.98 - $35.00
Volume99,300 shs
Average Volume93,470 shs
Market Capitalization$890.56 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Dova Pharmaceuticals (NASDAQ:DOVA)

Dova Pharmaceuticals logoDova Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD). The Company’s product candidate, avatrombopag is an orally administered thrombopoietin receptor agonist, or TPO-RA. The Company has completed pivotal Phase 3 clinical trials that evaluated avatrombopag for the treatment of thrombocytopenia in patients with CLD. The Company has not generated any revenue.

Receive DOVA News and Ratings via Email

Sign-up to receive the latest news and ratings for DOVA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:DOVA
CUSIPN/A
Phone919-806-4487

Debt

Debt-to-Equity RatioN/A
Current Ratio3.00%
Quick Ratio3.00%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees7
Outstanding Shares25,650,000

Dova Pharmaceuticals (NASDAQ:DOVA) Frequently Asked Questions

What is Dova Pharmaceuticals' stock symbol?

Dova Pharmaceuticals trades on the NASDAQ under the ticker symbol "DOVA."

How were Dova Pharmaceuticals' earnings last quarter?

Dova Pharmaceuticals Inc (NASDAQ:DOVA) issued its quarterly earnings results on Thursday, February, 15th. The company reported ($0.36) EPS for the quarter, meeting analysts' consensus estimates of ($0.36). During the same period in the prior year, the business earned ($0.44) earnings per share. View Dova Pharmaceuticals' Earnings History.

Where is Dova Pharmaceuticals' stock going? Where will Dova Pharmaceuticals' stock price be in 2018?

3 brokers have issued 12-month price targets for Dova Pharmaceuticals' stock. Their forecasts range from $32.00 to $35.00. On average, they anticipate Dova Pharmaceuticals' stock price to reach $33.33 in the next twelve months. View Analyst Ratings for Dova Pharmaceuticals.

Who are some of Dova Pharmaceuticals' key competitors?

Who are Dova Pharmaceuticals' key executives?

Dova Pharmaceuticals' management team includes the folowing people:

  • Paul B. Manning, Chairman of the Board (Age 61)
  • Alex Sapir, President, Chief Executive Officer, Director (Age 50)
  • Mark W. Hahn, Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer (Age 55)
  • Kevin Laliberte, Senior Vice President - Product Development (Age 39)
  • Lee F. Allen M.D., Ph.D., Chief Medical Officer (Age 65)
  • Sean Stalfort, Director (Age 47)
  • Steven M. Goldman, Independent Director (Age 65)
  • Roger A. Jeffs Ph.D., Independent Director (Age 55)
  • Alfred J. Novak, Independent Director (Age 69)

When did Dova Pharmaceuticals IPO?

(DOVA) raised $66 million in an initial public offering (IPO) on Thursday, June 29th 2017. The company issued 4,100,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and Leerink Partners acted as the underwriters for the IPO.

When did the company's lock-up period expire?

Dova Pharmaceuticals' lock-up period expired on Tuesday, December 26th. Dova Pharmaceuticals had issued 4,415,000 shares in its public offering on June 29th. The total size of the offering was $75,055,000 based on an initial share price of $17.00. Since the expiration of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.

Who owns Dova Pharmaceuticals stock?

Dova Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Perceptive Advisors LLC (7.05%), BlackRock Inc. (2.25%), Nexthera Capital LP (1.77%), Wells Fargo & Company MN (1.24%), Pier Capital LLC (0.62%) and Geode Capital Management LLC (0.24%). Company insiders that own Dova Pharmaceuticals stock include Alex Sapir, Kevin Laliberte, Lee F Md Phd Allen, Paul B Manning and Steven M Goldman. View Institutional Ownership Trends for Dova Pharmaceuticals.

Who sold Dova Pharmaceuticals stock? Who is selling Dova Pharmaceuticals stock?

Dova Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN. View Insider Buying and Selling for Dova Pharmaceuticals.

Who bought Dova Pharmaceuticals stock? Who is buying Dova Pharmaceuticals stock?

Dova Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Perceptive Advisors LLC, Pier Capital LLC, Goldman Sachs Group Inc., Nexthera Capital LP, Virtu Financial LLC, Virtus Fund Advisers LLC and Geode Capital Management LLC. Company insiders that have bought Dova Pharmaceuticals stock in the last two years include Alex Sapir, Kevin Laliberte, Lee F Md Phd Allen, Paul B Manning and Steven M Goldman. View Insider Buying and Selling for Dova Pharmaceuticals.

How do I buy Dova Pharmaceuticals stock?

Shares of Dova Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Dova Pharmaceuticals' stock price today?

One share of Dova Pharmaceuticals stock can currently be purchased for approximately $34.68.

How big of a company is Dova Pharmaceuticals?

Dova Pharmaceuticals has a market capitalization of $890.56 million. Dova Pharmaceuticals employs 7 workers across the globe.

How can I contact Dova Pharmaceuticals?

Dova Pharmaceuticals' mailing address is 240 Leigh Farm Road Suite 245, Durham NC, 27707. The company can be reached via phone at 919-806-4487 or via email at [email protected]


MarketBeat Community Rating for Dova Pharmaceuticals (DOVA)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  55 (Vote Outperform)
Underperform Votes:  56 (Vote Underperform)
Total Votes:  111
MarketBeat's community ratings are surveys of what our community members think about Dova Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Dova Pharmaceuticals (NASDAQ:DOVA) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.002.67
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $33.33$33.33$32.33$29.67
Price Target Upside: 16.43% upside16.43% upside44.02% upside30.40% upside

Dova Pharmaceuticals (NASDAQ:DOVA) Consensus Price Target History

Price Target History for Dova Pharmaceuticals (NASDAQ:DOVA)

Dova Pharmaceuticals (NASDAQ:DOVA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/28/2017Jefferies GroupBoost Price TargetBuy$33.00HighView Rating Details
9/26/2017Leerink SwannUpgradeMarket Perform -> Outperform$32.00HighView Rating Details
7/24/2017JPMorgan Chase & Co.Initiated CoverageOverweight -> Overweight$35.00HighView Rating Details
(Data available from 2/20/2016 forward)

Earnings

Dova Pharmaceuticals (NASDAQ:DOVA) Earnings History and Estimates Chart

Earnings by Quarter for Dova Pharmaceuticals (NASDAQ:DOVA)

Dova Pharmaceuticals (NASDAQ DOVA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/15/2018Q4 2017($0.36)($0.36)ViewN/AView Earnings Details
11/9/2017Q3 2017($0.30)($0.38)ViewN/AView Earnings Details
8/10/2017Q2 2017($0.24)($0.32)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Dova Pharmaceuticals (NASDAQ:DOVA) Earnings Estimates

2018 EPS Consensus Estimate: ($1.42)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.52)($0.42)($0.47)
Q2 20182($0.51)($0.45)($0.48)
Q3 20182($0.46)($0.16)($0.31)
Q4 20182($0.53)$0.21($0.16)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Dova Pharmaceuticals (NASDAQ:DOVA)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Dova Pharmaceuticals (NASDAQ DOVA) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 26.93%
Insider Trades by Quarter for Dova Pharmaceuticals (NASDAQ:DOVA)
Institutional Ownership by Quarter for Dova Pharmaceuticals (NASDAQ:DOVA)

Dova Pharmaceuticals (NASDAQ DOVA) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/16/2017Paul B ManningDirectorBuy25,870$22.30$576,901.00View SEC Filing  
8/15/2017Steven M GoldmanDirectorBuy20,169$22.23$448,356.8781,158View SEC Filing  
7/5/2017Alex SapirCEOBuy20,100$17.00$341,700.0020,100View SEC Filing  
7/5/2017Kevin LaliberteVPBuy6,200$17.00$105,400.006,200View SEC Filing  
7/5/2017Lee F Md Phd AllenInsiderBuy3,500$17.00$59,500.003,500View SEC Filing  
7/5/2017Steven M GoldmanDirectorBuy72,000$17.94$1,291,680.0042,000View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Dova Pharmaceuticals (NASDAQ DOVA) News Headlines

Source:
DateHeadline
Research Analysts Set Expectations for Dova Pharmaceuticals Incs FY2021 Earnings (DOVA)Research Analysts Set Expectations for Dova Pharmaceuticals Inc's FY2021 Earnings (DOVA)
www.americanbankingnews.com - February 19 at 9:22 AM
FY2022 Earnings Forecast for Dova Pharmaceuticals Inc Issued By Jefferies Group (DOVA)FY2022 Earnings Forecast for Dova Pharmaceuticals Inc Issued By Jefferies Group (DOVA)
www.americanbankingnews.com - February 19 at 9:18 AM
Dova Pharmaceuticals (DOVA) Upgraded by BidaskClub to BuyDova Pharmaceuticals (DOVA) Upgraded by BidaskClub to Buy
www.americanbankingnews.com - February 17 at 2:42 PM
-$0.47 EPS Expected for Dova Pharmaceuticals Inc (DOVA) This Quarter-$0.47 EPS Expected for Dova Pharmaceuticals Inc (DOVA) This Quarter
www.americanbankingnews.com - February 16 at 11:08 PM
Dova Pharmaceuticals (DOVA) Announces Quarterly  Earnings Results, Hits EstimatesDova Pharmaceuticals (DOVA) Announces Quarterly Earnings Results, Hits Estimates
www.americanbankingnews.com - February 16 at 10:56 AM
 Dova Pharmaceuticals Inc (DOVA) Given Average Rating of "Strong Buy" by Analysts Dova Pharmaceuticals Inc (DOVA) Given Average Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - February 16 at 10:21 AM
Dova Pharmaceuticals reports 4Q lossDova Pharmaceuticals reports 4Q loss
finance.yahoo.com - February 16 at 9:13 AM
Dova Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Operating and Financial ResultsDova Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Operating and Financial Results
finance.yahoo.com - February 15 at 4:29 PM
Dova Pharmaceuticals to Present at Leerink Partners 7th Annual Global Healthcare ConferenceDova Pharmaceuticals to Present at Leerink Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 13 at 9:03 AM
Dova Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results on February 15, 2018Dova Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results on February 15, 2018
finance.yahoo.com - February 12 at 4:37 PM
Zacks: Dova Pharmaceuticals Inc (DOVA) Receives Consensus Recommendation of "Strong Buy" from AnalystsZacks: Dova Pharmaceuticals Inc (DOVA) Receives Consensus Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - February 12 at 3:34 AM
Brokerages Expect Dova Pharmaceuticals Inc (DOVA) to Announce ($0.36) EPSBrokerages Expect Dova Pharmaceuticals Inc (DOVA) to Announce ($0.36) EPS
www.americanbankingnews.com - February 5 at 3:28 AM
 Dova Pharmaceuticals Inc (DOVA) Given $35.67 Consensus Price Target by Analysts Dova Pharmaceuticals Inc (DOVA) Given $35.67 Consensus Price Target by Analysts
www.americanbankingnews.com - February 1 at 1:28 AM
Dova Pharmaceuticals (DOVA) Appoints Mark Hahn as CFODova Pharmaceuticals (DOVA) Appoints Mark Hahn as CFO
www.streetinsider.com - January 30 at 4:32 PM
BRIEF-Dova Pharmaceuticals Announces Appointment Of Mark W. Hahn As Chief Financial OfficerBRIEF-Dova Pharmaceuticals Announces Appointment Of Mark W. Hahn As Chief Financial Officer
www.reuters.com - January 30 at 4:32 PM
Dova Pharmaceuticals (DOVA) versus Its Competitors Head to Head ContrastDova Pharmaceuticals (DOVA) versus Its Competitors Head to Head Contrast
www.americanbankingnews.com - January 29 at 9:16 PM
Zacks: Dova Pharmaceuticals Inc (DOVA) Receives Consensus Rating of "Strong Buy" from AnalystsZacks: Dova Pharmaceuticals Inc (DOVA) Receives Consensus Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - January 17 at 5:42 AM
Dova Pharmaceuticals (DOVA) & Its Competitors Financial AnalysisDova Pharmaceuticals (DOVA) & Its Competitors Financial Analysis
www.americanbankingnews.com - January 14 at 11:06 PM
-$0.36 EPS Expected for Dova Pharmaceuticals Inc (DOVA) This Quarter-$0.36 EPS Expected for Dova Pharmaceuticals Inc (DOVA) This Quarter
www.americanbankingnews.com - January 14 at 1:06 AM
Dova Pharmaceuticals (DOVA) Rating Increased to Hold at BidaskClubDova Pharmaceuticals (DOVA) Rating Increased to Hold at BidaskClub
www.americanbankingnews.com - January 13 at 5:38 PM
Jefferies Group Weighs in on Dova Pharmaceuticals Incs FY2022 Earnings (DOVA)Jefferies Group Weighs in on Dova Pharmaceuticals Inc's FY2022 Earnings (DOVA)
www.americanbankingnews.com - January 8 at 9:40 PM
BidaskClub Lowers Dova Pharmaceuticals (DOVA) to SellBidaskClub Lowers Dova Pharmaceuticals (DOVA) to Sell
www.americanbankingnews.com - January 6 at 11:08 AM
Dova Pharmaceuticals to Present at J.P. Morgan Healthcare ConferenceDova Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
finance.yahoo.com - January 3 at 5:52 PM
Dova Pharmaceuticals Provides Update on Development Strategy for Avatrombopag in Immune Thrombocytopenic Purpura (ITP) and Chemotherapy-Induced Thrombocytopenia (CIT)Dova Pharmaceuticals Provides Update on Development Strategy for Avatrombopag in Immune Thrombocytopenic Purpura (ITP) and Chemotherapy-Induced Thrombocytopenia (CIT)
finance.yahoo.com - January 3 at 5:52 PM
Zacks: Analysts Set $34.00 Target Price for Dova Pharmaceuticals Inc (DOVA)Zacks: Analysts Set $34.00 Target Price for Dova Pharmaceuticals Inc (DOVA)
www.americanbankingnews.com - January 2 at 8:02 AM
What Does Dova Pharmaceuticals Inc’s (NASDAQ:DOVA) Ownership Structure Look Like?What Does Dova Pharmaceuticals Inc’s (NASDAQ:DOVA) Ownership Structure Look Like?
finance.yahoo.com - December 21 at 5:47 PM
Dova Pharmaceuticals Incs Lock-Up Period Set To End  on December 26th (NASDAQ:DOVA)Dova Pharmaceuticals Inc's Lock-Up Period Set To End on December 26th (NASDAQ:DOVA)
www.americanbankingnews.com - December 19 at 1:14 AM
Zacks: Dova Pharmaceuticals Inc (DOVA) Given Consensus Rating of "Strong Buy" by BrokeragesZacks: Dova Pharmaceuticals Inc (DOVA) Given Consensus Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - December 17 at 7:28 PM
Dova Pharmaceuticals Announces Four Presentations at the 59th American Society of Hematology Annual MeetingDova Pharmaceuticals Announces Four Presentations at the 59th American Society of Hematology Annual Meeting
finance.yahoo.com - December 4 at 5:48 PM
 Dova Pharmaceuticals, Inc. (DOVA) Given Consensus Recommendation of "Strong Buy" by Brokerages Dova Pharmaceuticals, Inc. (DOVA) Given Consensus Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - December 2 at 9:52 AM
Dova Pharmaceuticals Inc (DOVA) And The Healthcare Sector Outlook 2017Dova Pharmaceuticals Inc (DOVA) And The Healthcare Sector Outlook 2017
finance.yahoo.com - December 1 at 4:20 PM
Dova Pharmaceuticals, Inc. (DOVA) Forecasted to Post Q4 2017 Earnings of ($0.34) Per ShareDova Pharmaceuticals, Inc. (DOVA) Forecasted to Post Q4 2017 Earnings of ($0.34) Per Share
www.americanbankingnews.com - November 30 at 11:02 AM
Dova Pharmaceuticals (DOVA) Price Target Raised to $33.00 at Jefferies GroupDova Pharmaceuticals (DOVA) Price Target Raised to $33.00 at Jefferies Group
www.americanbankingnews.com - November 28 at 6:30 PM
BRIEF-Dova Pharmaceuticals Announces FDA Acceptance Of The Avatrombopag New Drug Application With Priority ReviewBRIEF-Dova Pharmaceuticals Announces FDA Acceptance Of The Avatrombopag New Drug Application With Priority Review
www.reuters.com - November 27 at 6:01 PM
Dova Pharmaceuticals to Present at Evercore ISI ConferenceDova Pharmaceuticals to Present at Evercore ISI Conference
finance.yahoo.com - November 21 at 6:13 PM
 Dova Pharmaceuticals, Inc. (DOVA) Given Average Recommendation of "Strong Buy" by Brokerages Dova Pharmaceuticals, Inc. (DOVA) Given Average Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - November 17 at 3:32 PM
What You Must Know About Dova Pharmaceuticals Inc’s (DOVA) Financial StrengthWhat You Must Know About Dova Pharmaceuticals Inc’s (DOVA) Financial Strength
finance.yahoo.com - November 16 at 1:33 PM
Dova Pharmaceuticals, Inc. (DOVA) Cut to Hold at Zacks Investment ResearchDova Pharmaceuticals, Inc. (DOVA) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - November 14 at 10:26 PM
Dova Pharmaceuticals, Inc. (DOVA) Forecasted to Post Q1 2018 Earnings of ($0.42) Per ShareDova Pharmaceuticals, Inc. (DOVA) Forecasted to Post Q1 2018 Earnings of ($0.42) Per Share
www.americanbankingnews.com - November 13 at 6:00 AM
BRIEF-Dova Pharmaceuticals reports third quarter resultsBRIEF-Dova Pharmaceuticals reports third quarter results
www.reuters.com - November 10 at 6:24 PM
Dova Pharmaceuticals Reports Third Quarter 2017 Operating and Financial ResultsDova Pharmaceuticals Reports Third Quarter 2017 Operating and Financial Results
finance.yahoo.com - November 10 at 10:39 AM
Dova Pharmaceuticals reports 3Q lossDova Pharmaceuticals reports 3Q loss
finance.yahoo.com - November 10 at 10:39 AM
Dova Pharmaceuticals to Present at Jefferies 2017 London Healthcare ConferenceDova Pharmaceuticals to Present at Jefferies 2017 London Healthcare Conference
finance.yahoo.com - November 10 at 10:39 AM
Dova Pharmaceuticals, Inc. (DOVA) Posts Quarterly  Earnings Results, Misses Estimates By $0.08 EPSDova Pharmaceuticals, Inc. (DOVA) Posts Quarterly Earnings Results, Misses Estimates By $0.08 EPS
www.americanbankingnews.com - November 9 at 11:23 PM
Zacks: Dova Pharmaceuticals, Inc. (DOVA) Receives Consensus Recommendation of "Strong Buy" from AnalystsZacks: Dova Pharmaceuticals, Inc. (DOVA) Receives Consensus Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - November 2 at 3:30 AM
Head-To-Head Review: Dova Pharmaceuticals (DOVA) & Geron Corporation (GERN)Head-To-Head Review: Dova Pharmaceuticals (DOVA) & Geron Corporation (GERN)
www.americanbankingnews.com - October 30 at 11:40 AM
Dova Pharmaceuticals, Inc. (DOVA) Upgraded to "Buy" by Zacks Investment ResearchDova Pharmaceuticals, Inc. (DOVA) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - October 11 at 5:56 PM
Dova Pharmaceuticals to Present Phase 3 Avatrombopag Data at the 2017 Liver Meeting of the AmericanDova Pharmaceuticals to Present Phase 3 Avatrombopag Data at the 2017 Liver Meeting of the American
www.nasdaq.com - October 10 at 8:52 PM
Dova Pharmaceuticals to Present Phase 3 Avatrombopag Data at the 2017 Liver Meeting of the American Association for the Study of Liver Diseases (AASLD)Dova Pharmaceuticals to Present Phase 3 Avatrombopag Data at the 2017 Liver Meeting of the American Association for the Study of Liver Diseases (AASLD)
feeds.benzinga.com - October 10 at 4:47 PM
Zacks: Dova Pharmaceuticals, Inc. (DOVA) Given $32.33 Average Price Target by BrokeragesZacks: Dova Pharmaceuticals, Inc. (DOVA) Given $32.33 Average Price Target by Brokerages
www.americanbankingnews.com - October 5 at 2:40 PM

SEC Filings

Dova Pharmaceuticals (NASDAQ:DOVA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Dova Pharmaceuticals (NASDAQ:DOVA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Dova Pharmaceuticals (NASDAQ DOVA) Stock Chart for Tuesday, February, 20, 2018

Loading chart…

This page was last updated on 2/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.